Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression

Libo Sun†, Xingyi Jin†, Lijuan Xie2, Guangjun Xu3, Yunxia Cui3 and Zhuo Chen1*

Abstract

Background: Swainsonine is a natural indolizidine alkaloid, its anti-tumor activity has been widely reported in varied cancers. This study aimed to investigate whether Swainsonine exerted anti-tumor impact on glioma cells, likewise uncovered the relative molecular mechanisms.

Methods: After administration with diverse concentrations of Swainsonine, cell growth, migration and invasion in U251 and LN444 cells were appraised by the common-used CCK-8, BrdU, flow cytometry and Transwell assays. MiR-92a mimic, inhibitor and the correlative NC were transfected into U251 and LN444 cells, and assessment of miR-92a expression was by utilizing qRT-PCR. Functions of miR-92a in above-mentioned cell biological processes were analyzed again in Swainsonine-treated cells. The momentous proteins of cell cycle, apoptosis and PI3K/AKT/mTOR pathway were ultimately examined by western blot.

Results: Swainsonine significantly hindered cell proliferation through decreasing cell viability, declining the percentage of BrdU cells, down-regulating CyclinD1 and up-regulating p16 expression. Enhancement of percentage of apoptotic cells was presented in Swainsonine-treated cells via activating cleaved-Caspase-3 and cleaved-Caspase-9. Additionally, Swainsonine impeded the abilities of migration and invasion by decreasing MMP-2, MMP-9, Vimentin and E-cadherin. Repression of miR-92a was observed in Swainsonine-treated cells, and miR-92a overexpression overturned the anti-tumor activity of Swainsonine in glioma cells. Finally, western blot assay displayed that Swainsonine hindered PI3K/AKT/mTOR pathway via regulating miR-92a.

Conclusions: These discoveries corroborated that Swainsonine exerted anti-tumor impacts on glioma cells via repression of miR-92a, and inactivation of PI3K/AKT/mTOR signaling pathway.

Keywords: Swainsonine, microRNA-92a, Glioma, Proliferation, PI3K/AKT/mTOR

Background

Glioma is the most familiar primary tumor in the central nervous system, most of which present aggressive growth [1]. Glioma comprise approximately 80% of all malignant brain tumors, the high recurrence rate, high disability rate and high mortality of glioma have seriously threatened the health of human [2]. The symptoms and signs caused by glioma mainly depend on its space-occupying effect and the function of brain regions [3]. Because of its space-occupying effect, glioma can cause headache, nausea and vomiting, epilepsy and blurred vision [4]. Surgery, chemotherapy and radiotherapy remain the main methods for the treatment of glioma [5, 6]. Although the treatment techniques for glioma have been greatly improved in recent years, the treatment effect is still unsatisfactory. Thus, study and exploration of new method for the treatment of glioma is necessary.

Swainsonine (C₈H₁₅NO₃, M: 173.2096) is a kind of indolizidine alkaloid, which is firstly isolated from Swainsonacanescens, and then identified in many Astragalus and Oxytropis species [7]. A large number of experimental results demonstrated that Swainsonine exerted anti-tumor effect on the different cancers [8, 9]. Dennis et al. firstly testified that Swainsonine could impede the growth of...
human tumors [10]. It has been showed that Swainsonine could directly suppress colon cancer cells growth and enhance the immune function [11]. Additionally, Chen et al. reported that Swainsonine could inhibit esophageal carcinoma Eca-109 cells proliferation in a dose-dependent manner [12]. Further, increasing evidence revealed that Swainsonine could decline the ability of tumor cell metastasis [13]. As Korczak et al. displayed that Swainsonine could inhibit breast cancer cells infiltration and invasion [14]. However, the influences and the molecular mechanisms of Swainsonine in glioma cells are still inadequate in the existing studies.

MicroRNA-92a (miR-92a) is a momentous member of miR-17-92 cluster, which has been discovered to be involved in mediating cell viability, apoptosis and metastasis in various cancers [15, 16]. Evidence from Zhou et al. affirmed that increased miR-92a was observed in cervical cancer, moreover, miR-92a could inhibit breast cancer cells growth and enhance the immune function [17]. However, there are few reports about miR-92a in glioma. Thus, the intent in the present study is to explore the anti-tumor activity of Swainsonine in glioma cells, meanwhile to confirm the relationship between Swainsonine and miR-92a in glioma cells. The signaling pathway of PI3K/AKT/mTOR was examined to uncover the underlying molecular mechanism. The findings might provide more evidences to prove the anti-tumor effect of Swainsonine on glioma, and might favor for the further expansion the clinical application of Swainsonine.

Methods

Cell culture and treatment

U251 and LN444 glioma cells and NHA cells (normal human astrocyte cell line) were obtained from Shanghai Institute for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). U251 cell line was originally derived from astrocytoma carcinoma of a 75 years old male. LN444 cell line was originally derived from normal human astrocytes. These cell lines have been authenticated by using Single Tandem Repeat (STR) profiling method. There is no mycoplasma contamination in U251, LN444 and NHA cell lines. Frequently-used RPMI-1640 medium containing 10% fetal bovine serum (FBS) was obtained from Gibco (Thermo Fisher Scientific Inc., Waltham, MA, USA), which was used to culture U251 cells at 37 °C in a 5% CO₂ incubator. LN444 cells and normal astrocyte NHA cells were grown in DMEM (Gibco) encompassing 10% FBS and 1x antibiotic/antimycotic in a CO₂ (5%) incubator at 37 °C. Swainsonine attained from Sigma (St. Louis, MO, USA) was dissolved in PBS (Gibco), and adjusted the concentrations to 0, 10, 20, 30 and 40 μM for administrating U251 and LN444 cells in the next experiments. These cells were pre-exposed Swainsonine for 12 h.

Cell viability assay

Cell Counting Kit-8 (CCK-8, Dojindo, Gaithersburg, MD) was employed to analyze the ability of U251 and LN444 cells after administration with Swainsonine. Briefly, U251 and LN444 cells were cultivated in 96-well plate and then disposed with 10, 20, 30 and 40 μM of Swainsonine for 12 h. After this, the 10 μL CCK-8 solution was supplemented into the culture plates, and co-incubated with U251 and LN444 cells for extra 1 h under the condition of routine culture. The optical density (OD) values at 450 nm were executed via exploiting a Microplate Reader (Bio-Rad, Hercules, CA, USA).

Proliferation assay

On the basis of the specifications of Bromodeoxyuridine (BrdU, Sigma), Cell proliferation was probed into U251 and LN444 cells. In brief, U251 and LN444 cells were incubated in 6-well plate for 24 h, and administrated with 30 μM of Swainsonine for 12 h. After stimulation, 10 μM BrdU was mixed into the cell plate, meanwhile co-incubated with U251 and LN444 cells for another 4 h at 37 °C. Subsequently, U251 and LN444 cells were bap-tized twice with PBS, and subsequently settled with methyl alcohol (Sigma) for 10 min, as well as 300 μL anti-BrdU (ab1893, Abcam, Cambridge, UK) at dilution of 1:1000 was mixed into the cell plate and co-incubated overnight at ambient temperature. The percentage of BrdU positive cells was finally counted by utilizing microscope (Olympus Optical, Tokyo, Japan).

Cell cycle assay

Cell Cycle and Apoptosis Analysis Kit (Beyotime, Shanghai, China) was exploited to determine cell cycle based on the specifications. U251 cells were stimulated with 30 μM Swainsonine for 12 h. Next, these treated cells were bap-tized with PBS for two times, and fixed in 70% ethanol at 4 °C overnight. After this, U251 cells were re-suspended in 500 μL of PBS encompassing 0.2 mg/mL RNase A and 50 μg/mL PI for staining cells for 30 min in the dark at ambient temperature. The percentages of cells of G0/G1, S, and G2/M were counted exploiting FACScan flow cytometer (Becton Dickinson, San Jose, USA).

Apoptosis assay

Common-used Annexin V-FITC/PI apoptosis detection kit (Becton-Dickinson, Franklin Lakes, NJ, USA) was utilized to examine the percentage of apoptotic cells as described previously [18]. After stimulation with 30 μM of Swainsonine for 12 h, U251 and LN444 cells were
baptized in PBS, and stained with 5 μL PI/FITC-Annexin V for 30 min in the absence of light at ambient temperature. After staining, cell apoptosis was straightforwardly evaluated by utilizing flow cytometry analysis (Beckman Coulter, Fullerton, CA, USA).

Migration and invasion assay
The Transwell migration assay and Transwell invasion assay with a pore size of 8 μm were performed to appraise the abilities of U251 and LN444 cells migration and invasion. In brief, U251 and LN444 cells were pre-exposed with 30 μM Swainsonine for 12 h. Then, 200 μL serum-free medium was filled into the upper compartment of 24-well Transwell culture chamber. Synchronously, 600 μL complete medium was added into the lower chamber. After cultivation, U251 and LN444 cells were immobilized with methanol (Sigma) for 30 min. Non-traversed cells were moved by exploiting a cotton swab from the upper surface of the filter. Traversed cells were subsequently stained with 0.1% crystal violet (Merck, Darmstadt, Germany) for 20 min. After reaction, the stained cells were counted by utilizing a microscope (Leica Microsystems, Wetzlar, Germany). For detection of cell invasion, the inserts were covered with BD Matrigel™ Matrix (BD Biosciences, Bedford, MA, USA).

Wound healing assay
The treated U251 cells were cultivated in a CO₂ (5%) incubator at 37 °C until 80–90% confluence. Then, these cells were subjected to 10 μg/mL of mitomycin C in wound healing assay. Cell migration was evaluated via measuring the movement of cells into the acellular area created by a sterile insert. After 0, 12, 24 h, 36 and 48 h, the wound closure was observed. The scratch wound closure percent was calculated as (the scratch area before incubation) × 100% / (the scratch area after incubation) × 100%.

Transfection
MiR-92a mimic, miR-92a inhibitor and the correlative negative control (NC) (GenePharma Co., Shanghai, China) were utilized to transfect into U251 and LN444 cells on the basis of the experience of liposome transfection by utilizing Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA). Above-mentioned transfected cells were gathered after 48 h transfection and were exploited to the next studies.

Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated from U251 and LN444 cells accompanied by Swainsonine administration or miR-92a mimic/inhibitor transfection by exploiting Trizol reagent (Life Technologies, Carlsbad, CA, USA) following its specifications. The reversed transcription and qRT-PCR analysis were performed by utilizing Taqman MicroRNA Reverse Transcription Kit and Taqman Universal Master Mix II (Biosystems, Foster City, CA, USA) to examine the expression level of miR-92a in the Swainsonine-treated cells or miR-92a mimic/inhibitor transfected cells. U6 was selected and employed as the most stable endogenous control in this experiment. These data was calculated by the 2−ΔΔCT method [19].

Western blot assay
The proteins expressed in Swainsonine-treated cells or miR-92a-transfected cells were extracted by exploiting RIPA (Beyotime Biotechnology, Shanghai, China) lysis buffer. BCA™ Protein Assay Kit (Pierce, Appleton, WI, USA) was employed to analyze the concentrations of total protein samples. Above protein simples were separated by 10% SDS-PAGE and next transected to PVDF membranes. After sealing with 5% non-fat milk, the membranes were co-cultivated with the primary antibodies of CyclinD1 (ab134175), Cyclin-dependent kinase 4 (CDK4, ab199728), p16 (ab51243), pro-Caspase-3 (ab32150), cleaved-Caspase-3 (ab2302), pro-Caspase-9 (ab138412), cleaved-Caspase-9 (ab2324), matrix metalloproteinase-2 (MMP-2, ab37150), matrix metalloproteinase-9 (MMP-9, ab38898), Vimentin (ab16700), E-cadherin (ab15148), t-PI3K (ab191606), phosphorylated (p)-PI3K (ab182651), t-AKT (ab227100), p-AKT (ab13458), t-PI3K (ab32028), p-mTOR (ab109268), β-actin (ab8227, Abcam) and t-phosphorylated and total 70-kDa ribosomal protein S6 kinase (p70S6K, K2,078), p-p70S6K (#9204, all from Cell Signal Technology) overnight at 4 °C. Afterward, the second antibody (ab205718, 1:2000, Abcam) was co-incubated with above membranes for another 1 h at ambient temperature. The specific blots were visualized by the common-used ECL reagents (Super Signal Dura kit, Pierce, IL, USA). The intensity of these specific bands was quantified through Image Lab™ Software (Bio-Rad).

Statistical analysis
Three reduplicative experiments were presented in the current study. The results from above-mentioned experiments are exhibited as the mean ± SD. Graphpad statistical software (La Jolla, CA, USA) was employed to figure out the statistical results in disparate groups. The p-values were calculated utilizing ANOVA, and p < 0.05 was deemed to be a statistically significant result.

Results
Swainsonine inhibited glioma cells growth
Swainsonine is an indolizidine alkaloid, which obtains from Swainsonacanescens, the chemical structure of Swainsonine was showed in Fig. 1. We first used different
dosages of Swainsonine (0, 10, 20 and 40 μM) to dispose human normal astrocyte cell line NHA for testing the impacts of Swainsonine on cell cytotoxicity of normal brain cells. We discovered that Swainsonine stimulation had no appreciable effect on cell viability at the concentrations of 10–30 μM, while Swainsonine at the concentration of 40 μM was obviously decreased cell viability (p < 0.05, Fig. 2a), hinting that Swainsonine at the concentrations of 10–30 μM had no cytotoxicity in normal brain cells. To investigate the functions of Swainsonine in U251 and LN444 cells growth, cell proliferation and apoptosis were examined in U251 and LN444 cells after administration with diverse dosages of Swainsonine. Fig. 2b showed that cell viability was evidently impeded by Swainsonine at the concentrations of 20, 30 and 40 μM (p < 0.05, p < 0.01 or p < 0.001) in U251 cells. Subsequently, 30 μM Swainsonine was elected as the optimum concentration for exploiting in the following experiments. BrdU assay disclosed that the percentage of the BrdU positive cells was declined in U251 cells after administration with Swainsonine (p < 0.01, Fig. 2c). Similar results were presented in LN444 cells (p < 0.05, p < 0.01 or p < 0.001, Additional file 1: Figure S1A and 1B). Cell cycle assay results displayed that the percentage of G2/M phase cells were enhanced, but the percentage of G0/G1 phase cells were lowered after disposing with Swainsonine in U251 cells, indicating that Swainsonine could induce cell cycle arrest at G2/M phase (Fig. 2d). In Fig. 2e and f, we observed that Swainsonine notably down-regulated CyclinD1 and CDK4 protein levels, but increased p16 protein level as compared with control group (p < 0.05). Flow cytometry assay disclosed that cell apoptosis was significantly accelerated in U251 cells after administration with Swainsonine (p < 0.001, Fig. 2g). Meanwhile, cleaved-Caspase-3 and cleaved-Caspase-9 expression were obviously increased by Swainsonine (Fig. 2h). The impacts of Swainsonine on cell apoptosis and cell growth-associated factors in U251 (Fig. 2e-h) were similar with that in LN444 cells (p < 0.01 or p < 0.001, Additional file 1: Figure S1C-1F). All above results demonstrated that Swainsonine regulated glioma cell proliferation and apoptosis.

Swainsonine suppressed glioma cells migration and invasion
Next, we investigated the influences of Swainsonine in the abilities of cell migration and invasion in U251 and LN444 cells. Cell migration was evidently repressed by Swainsonine, meanwhile MMP-2 and MMP-9 were also declined in Swainsonine-treated U251 cells (p < 0.05, Fig. 3a-c). The same inhibition was observed in cell invasion and Vimentin and E-cadherin expression. The results presented in Fig. 3d-f revealed that Swainsonine significantly inhibited the ability of cell invasion, as well as hindered Vimentin and enhanced E-cadherin in U251 cells (p < 0.01). The effect of Swainsonine on cell migration and invasion in LN444 cells showed the similar results as Fig. 3a-f (p < 0.01 or p < 0.001, Additional file 2: Figure S2). The data indicated that Swainsonine exerted the repressive effect on glioma cell migration and invasion. To exclude the impacts of cell viability on migration or invasion, we appraised the migration ability by utilizing wound healing assay after adding mitomycin C (10 g/mL) in U251 cells. We observed that mitomycin C evidently restrained cell viability. After administration of mitomycin C for 24, 36 and 48 h, we observed that Swainsonine significantly decreased the percentage of migration scratch coverage (p < 0.05 or p < 0.01, Fig. 3h). These discoveries further indicated that Swainsonine could reduce glioma cell migration and invasion.

Swainsonine restrained miR-92a expression in glioma cells
The relationship between Swainsonine and miR-92a in U251 and LN444 cells was analyzed by exploiting qRT-PCR. Swainsonine signally restrained miR-92a expression in U251 cells (p < 0.01, Fig. 4), implying a negative correlation between Swainsonine and miR-92a. The results in LN444 cells revealed that miR-92a expression was remarkably impeded in Swainsonine-treated cells (p < 0.01, Additional file 3: Figure S3). Above-mentioned data hinted that miR-92a might be a key regulator in Swainsonine-affected glioma cells.
Swainsonine mediated cell growth, migration and invasion via restraining miR-92a

To further explore the impacts of miR-92a on cell growth, migration and invasion, miR-92a mimic, inhibitor and the NC were transfected into U251 cells to up-regulate or down-regulate miR-92a expression. The transfection efficiency results presented in Fig. 5a disclosed that miR-92a was significantly increased by miR-92a overexpression, but decreased by miR-92a suppression in U251 cells (p < 0.01), suggesting the transfection efficiency was well, and miR-92a mimic and miR-92a inhibitor were successfully transfected into U251 cells. Next, we discovered that the inhibitory activity of Swainsonine on cell proliferation was reversed by miR-92a overexpression, as miR-92a overexpression accelerated the ratio of BrdU positive cells and up-regulated CyclinD1, CDK4, and p16 expression (p < 0.05, p < 0.01 or p < 0.001, Fig. 5b-d). Additionally, overexpression of miR-92a significantly reduced cell apoptosis and declined cleaved-Caspase-3 and cleaved-Caspase-9 levels in Swainsonine-treated U251 cells (p < 0.05, Fig. 5e and f).

Besides, the abilities of migration and invasion were evidently promoted by miR-92a overexpression in Swainsonine-treated U251 cells, as well as MMP-2, MMP-9, and Vimentin were also increased by miR-92a overexpression, however, E-cadherin was decreased by miR-92a overexpression in Swainsonine-treated U251 cells (p < 0.05, p < 0.01 or p < 0.001, Fig. 5g-l). Suppression of miR-92a showed the opposite regulatory effect on above-mentioned processes in Swainsonine-treated U251 cells (p < 0.05, p < 0.01 or p < 0.001, Fig. 5b-l). These data indicated that Swainsonine exhibited the anti-tumor activity might via restraining miR-92a expression in U251 cells.

Swainsonine hindered PI3K/AKT/mTOR pathway via repressing miR-92a expression

We eventually explored the effect of Swainsonine on PI3K/AKT/mTOR signaling pathway. We found that Swainsonine notably inhibited phosphorylated PI3K, AKT, mTOR and p70S6K in U251 cells (p < 0.05 or p
But, the repressive effect of Swainsonine on this pathway was reversed by miR-92a overexpression \( (p < 0.001, \text{Fig. 6a-d}) \). Suppression of miR-92a exerted the similar repressive effect of Swainsonine on PI3K/AKT/mTOR pathway \( (p < 0.05 \text{ or } p < 0.001, \text{Fig. 6a-d}) \). No appreciable effect on PI3K, AKT, mTOR and p70S6K in U251 cells. Above data indicated that Swainsonine impeded the activation of PI3K/AKT/mTOR pathway via restraining miR-92a expression in U251 cells.

**Discussion**

Herein, the investigations disclosed that Swainsonine significantly restrained glioma cell growth, cell migration and invasion. Decreased miR-92a expression was observed in Swainsonine-treated cells. Moreover, miR-92a overexpression facilitated cell growth, migration, and invasion in Swainsonine-treated cells. Besides, we found that Swainsonine hindered PI3K/AKT/mTOR pathway by down-regulation of miR-92a in U251 cells.
Accumulating evidences have demonstrated that TCMs, such as ginsenoside, paclitaxel and tanshinone, exhibited anti-tumor activity in glioma cells through affecting glioma cells cycle, regulating immune function, inhibiting cell angiogenesis, as well as mediating cell proliferation, metastasis and apoptosis [20–22]. Swainsonine is a natural alkaloid, and the anti-tumor effect of Swainsonine has been observed in various cancers, encompassing gastric cancer, lung cancer and esophageal cancer [13, 23, 24]. It has been demonstrated that Swainsonine induced lung cancer A549 cells apoptosis, and inhibited tumor growth in vivo [23]. Ma et al. explained that Swainsonine could suppress esophageal cancer cells invasion and epithelial-mesenchymal transition (EMT) process by regulation of Twist1 [24]. Sun et al. testified that Swainsonine could restrain C6 glioma cells growth in vitro, and decrease the tumor weight in vivo [25]. Above evidences clearly confirmed the anti-tumor activity of Swainsonine in the diverse cancers. Nevertheless, the impact of Swainsonine on U251 and LN444

![Fig. 4](Image)

**Fig. 4** Swainsonine repressed miR-92a expression in U251 cells. After disposing with 30 μM Swainsonine for 12 h, miR-92a expression was analyzed by utilizing quantitative real-time polymerase chain reaction (qRT-PCR) assay in U251 cells. *P < 0.01

![Fig. 5](Image)

**Fig. 5** Swainsonine affected glioma cell growth, migration and invasion by regulating miR-92a. MiR-92a mimic, inhibitor and the relevant negative control (NC) were transfected into U251 cells, and (a) the transfection efficiency of miR-92a mimic and miR-92a inhibitor was appraised by quantitative real-time polymerase chain reaction (qRT-PCR); (b) BrdU positive cells was detected by Bromodeoxyuridine (BrdU) assay; (c) and (d) CyclinD1, Cyclin-dependent kinase 4 (CDK4), and p16 were appraised by western blot; (e) and (f) cell apoptosis and pro-Caspase-3, pro-Caspase-9, cleaved-Caspase-3 and cleaved-Caspase-9 were appraised by utilizing flow cytometry and western blot assays; (g) cell migration, invasion, the protein levels of matrix metalloproteinase (MMP)-2/−9, Vimentin and E-cadherin were detected by Transwell and western blot assays. *P < 0.05; **P < 0.01; ***P < 0.001
cells remains unclear. We found that Swainsonine could suppress cell proliferation, migration, invasion, and induce apoptosis in U251 and LN444 cells, indicating the anti-tumor activity of Swainsonine in glioma cells.

miR-92a is a momentous member of miR-17-92 family, and abnormal expressed miR-92a has been found in various cancers [26, 27]. An important study from Ke et al. demonstrated that miR-92a-3p acted as an onco-miR in colorectal cancer cells via mediating PTEN/PI3K/AKT pathway [28]. In glioma, several studies have reported that miR-92a was increased in glioma cells and tissues, and down-regulation of miR-92a could decline glioma cells proliferation and induce apoptosis [29, 30]. Study from Niu et al. corroborated that miR-92a boosted proliferation and decreased apoptosis in glioma cells through regulation of apoptosis signaling pathways, indicating a novel oncogenic role in glioma cells [31]. In our study, we discovered that miR-92a expression was restrained in Swainsonine-treated cells, hinting that miR-92a might play a vital role in the development of glioma. To further confirm the hypothesis, we exploited the plasmids of miR-92a mimic and miR-92a inhibitor to alter miR-92a expression in glioma cells. Interesting results disclosed that miR-92a overexpression enhanced cell growth, migration and invasion in U251 cells after treatment with Swainsonine. Above data implied that miR-92a might impeded the anti-tumor activity of Swainsonine in glioma cells.

The alteration of major signaling pathways has been certified to be linked to the development of cancers, including glioma [32–34]. PI3K/AKT/mTOR pathway is an intracellular signaling pathway important in mediating cell cycle, and closely related to cellular quiescence, proliferation, apoptosis and metastasis [35, 36]. Both in vivo and in vitro experiments have testified that activation of PI3K/AKT/mTOR pathway could affect glioma cells proliferation, migration, and apoptosis, simultaneously regulate tumor formation in mice model [37, 38]. Study from Jiang et al. found that resveratrol...
down-regulated PI3K/AKT/mTOR pathway in U251 cells, thereby mediating U251 cells apoptosis [39]. Similar with the study, we found that Swainsonine notably hindered PI3K/AKT/mTOR pathway in U251 cells. In terms of miR-92a, Xiao et al. attested that miR-92a could promote tumor growth of osteosarcoma by targeting PTEN/AKT pathway [40]. Additionally, Song et al. demonstrated that miR-92a functioned in glioma cells by mediating CDH1/β-catenin and Notch-1/AKT pathways [29]. However, whether miR-92a participates in mediating PI3K/AKT/mTOR pathway in glioma cells remained unclear. In this study, we found that the repressive effect of Swainsonine on PI3K/AKT/mTOR signaling pathway was reversed by overexpression of miR-92a, indicating that Swainsonine hindered PI3K/AKT/mTOR pathway might be through restraining miR-92a expression in glioma cells.

Conclusions
Taken together, the study uncovered the functions and mechanism of Swainsonine on glioma cells. These data demonstrated that Swainsonine could inhibit PI3K/AKT/mTOR signaling pathway through down-regulation of miR-92a, thereby restraining cell growth, migration and invasion. These finding indicated that Swainsonine might exert anti-tumor activity in glioma cells, and might represent a potential therapeutic candidate for the treatment of glioma.

Additional files

**Additional file 1**  Figure S1. Swainsonine inhibited LN444 cells proliferation and induced apoptosis. LN444 cells were disposed with the diverse dosages of Swainsonine (0–40 μM) for 12 h. (A) Cell viability; (B) cell proliferation and (C and D) CyclinD1, Cyclin-dependent kinase 4 (CDK4), and p16 were appraised by Cell Counting Kit-8 (CCK-8), Bromo-deoxyuridine (BrdU) and western blot; (E) cell apoptosis and (F) pro-Caspase-3, pro-Caspase-9, cleaved-Caspase-3 and cleaved-Caspase-9 were assessed by flow cytometry and western blot. *p < 0.05; **p < 0.01; ***p < 0.001. (TIF 1854 kb)

**Additional file 2**  Figure S2. Swainsonine restrained LN444 cells migration and invasion. LN444 cells were administered with 30 μM Swainsonine for 12 h. (A-C) cell migration, and matrix metalloproteinase (MMP)-2/-9 were detected by Transwell and western blot assays; (D-F) cell invasion as well as Vimentin and E-cadherin were detected by Transwell and western blot assays. **p < 0.01; ***p < 0.001. (TIF 1228 kb)

**Additional file 3**  Figure S3. Swainsonine repressed miR-92a expression in LN444 cells. LN444 cells were disposed with 30 μM Swainsonine for 12 h, and miR-92a expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) assay. **p < 0.01. (TIF 138 kb)

Abbreviations

AKT: Protein kinase B; ANOVA: A one-way analysis of variance; COX-8: Cell Counting Kit-8; CDK4: Cyclin-dependent kinase 4; DIME: Dulbecco’s modified Eagle medium; ECL: Enhanced chemiluminescence; EMT: Epithelial-mesenchymal transition; FBS: Fetal bovine serum; FBXW7: F-box and WD repeat domain-containing 7; FITC: Fluorescein isothiocynate; miR-92a: MicroRNA-92a; MMP-2: Matrix metalloproteinase-2; MMP-9: Matrix metalloproteinase-9; mTOR: Mammalian target of rapamycin; OD: Optical density; p70S6K: Phosphorylated and total 70-kDa ribosomal protein S6 kinase; PBS: Phosphate-buffered saline; PI: Propidium iodide; PI3K: Phosphatidylinositol-3 kinase; PVDF: Polyvinylidene fluoride; qRT-PCR: Quantitative real-time polymerase chain reaction; RIPA: Radio immunoprecipitation assay; RPMI: Roswell Park Memorial Institute; SD: Standard deviation; TCM: Traditional Chinese medicine

Acknowledgements
Not applicable.

Funding
No specific funding was received for this study.

Availability of data and materials
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
LS, XJ and ZC designed, analyzed, reviewed, and wrote this work. LS, XJ, LX, GX, YC, and ZC analyzed and wrote this work. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable. The glioma cell lines U251 and LN444 and human normal astrocyte cell line NHA were obtained from Shanghai Institute for Biological Sciences, Chinese Academy of Sciences (Shanghai, China), and did not require ethics approval for their use in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Neurosurgery, China-Japan Union Hospital of Jilin University, No.126, Xiantai Street, Changchun 130033, Jilin Province, China. 2Department of Vascular Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China. 3Department of Science and Education, China-Japan Union Hospital Union Hospital of Jilin University, Changchun 130033, Jilin Province, China.

Received: 18 April 2018 Accepted: 1 March 2019 Published online: 19 March 2019

References
1. Fan YH, Xiao B, Lv SG, Ye MH, Zhu XG, Wu MJ. Lentivirus-mediated knockdown of chondroitin polymerizing factor inhibits glioma cell growth in vitro. Oncol Rep. 2017;38(2):1149–55.
2. Luo D, Chen W, Tian Y, Li J, Xu X, Chen C, Li F. Serpin peptidase inhibitor, clade a member 3 (SERPINA3), is overexpressed in glioma and associated with poor prognosis in glioma patients. Onco Targets Ther. 2017;10:2173–81.
3. Beez T, Burgula S, Kamp M, Rapp M, Steiger HJ, Sabel M. Space-occupying tumor bed cysts as a complication of modern treatment for high-grade glioma. World Neurosurg. 2017;104:81–8.
4. Donner L, Ulmer S, Rohr A, Mehdorn HM, Nabavi A. Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel (R) implantation–incidence, therapeutic strategies, and outcome. J Clin Neurosci. 2011;18(3):347–51.
5. Taunk NK, Moraes FY, Escorca FE, Mendez LC, Beal K, Marta GN. External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma. Expert Rev Anticancer Ther. 2016;16(3):347–58.
6. Wang Z, Yang G, Zhang YY, Yao Y, Dong LH. A comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(44):e8444.
17. Zhou C, Shen L, Mao L, Wang B, Li Y, Yu H. miR-92a is upregulated in cervical cancer tissue and promotes cell migration and invasion by targeting FBXW7. Biochem Biophys Res Commun. 2015;458(1):63–69.

18. Moradi MT, Karimi A, Alidadi S. In vitro antiproliferative and apoptosis-inducing effects of crude ethyl alcohol extract of Quercus brantii L. on human U251 glioma cells. J Exp Clin Cancer Res. 2016;35:52–59.

19. Cao W, Chen C, Sun C, Xu Y, Wang T, Zhang H, Li F, et al. miR-92a inhibits proliferation and induces apoptosis by regulating methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) expression in acute myeloid leukemia. Oncol Res. 2017;25(7):1069–79.

20. Sun C, Yu Y, Wang N, Chen C, Wang L, Zhang H, Li F, et al. miR-92a is a critical regulator of the apoptosis pathway in glioblastoma. Oncol Rep. 2017;28(5):1771–76.

21. Ying P, Qiu Z, Yuan J, Lei D, Yang W, Chao G, Li G, Yu Z. Silencing of cZNF292 circular RNA suppresses human glioma tube formation via the Wnt/B-catenin signaling pathway. Oncotarget. 2016;7(39):53449–55.

22. Zhu Y, Zhang A, Qi L, Cai Y, Yang P, Xuan G, Jiang Y. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget. 2016;7(42):14429–40.

23. Editors TPO. Retraction: Baicalein reduces the invasion of glioma cells via reducing the activity of p38 signaling pathway. Plos One. 2016;11(7):e0160194.

24. King D, Yeomanson D, Bryant HE. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol. 2015;37(4):245–51.

25. Jiao D, Wang J, Lu W, Tang X, Chen J, Mou H, Chen QY. Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. Mol Ther Oncolytics. 2016;3:16018.

26. Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22):33440–50.

27. Lin F, de Gooyer MC, Hanekamp D, Chandrasekaran G, Bull LC, Thota N, Spardians RW, Beijnen JH, Wurdinger T, van Tellingen O. PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clin Cancer Res. 2017;23(5):1286–98.

28. Jiang H, Shang X, Wu H, Gautham SC, Al-Holou S, Li C, Kuo J, Zhang L, Chopp M. Revertadon downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol. 2009;8(1):25–33.

29. Xiao J, Yu W, Hu K, Li M, Chen J, Li Z. miR-92a promotes tumor growth of osteosarcoma by targeting PI3K/AKT signaling pathway. Oncol Rep. 2017;37(4):2513–21.